
Please type a plus sign (+) inside this box Under the Paperwork Reduction Act of 1995, no pers valid OMB control number.	Patent and Trademark Office: U.	(Modified) PTO/SB/21 (6-98) trough 09/30/2000. OMB 0651-0031 S. DEPARTMENT OF COMMERCE ion of information unless it displays a
Colonia	Application Number	09/394,019
RANSMITTAL	Filing Date	September 10, 1999
ADEMAN FORM	First Named Inventor	Akira Komoriya
(to be used for all correspondence after initial filing)	Group Art Unit	1653
	Examiner Name	Robinson, P.
Total Number of Pages in This Submission	Attorney Docket Number	300-903830US

INN S	*** FRANSMITTAL		Filing Date		September 10, 1999		
ARDY.	FORM (to be used for all correspondence after initial filing)			First Named Inve	ntor	Akira Komoriya	
Ø	(to be used for all correspondence after initial filing)		er initial filing)	Group Art Unit		1653	
				Examiner Name		Robinson, P.	
	Total Number of	Pages in This Subm	ission	Attorney Docket N	umber	300-903830US	
			ENCLOS	SURES (check all th	hat apply	(v	
	Fee Transmit	ttal Form ttached		nent Papers Application) (s)		After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences	
LYFUED	X Amendment / Response		Licensin	g-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
	After	Final	Petition and Acc	Routing Slip (PTO/SB companying Petition	3/69)	Proprietary Information	
	Affida	avits/declaration(s)	1 1	to Convert to a nal Application		Status Letter	
/	Extension of	Time Request	Power of Change Address	f Attorney, Revocatior of Correspondence		X Additional Enclosure(s) (please identify below):	
	Express Aba	indonment Request		I Disclaimer		receipt acknowledgment postcard	
	Information (Disclosure Statement	1 —	ntity Statement			
	Certified Copy of Priority		Request for Refund				
	Document(s	o Missing Parts/	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.				
	Incomplete Application Response to Missing		Remarks			RECEIVE	
	Parts	under 37 CFR		_		JUN 2 7 2002	
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT TECH CENTER 1600 29						
	Firm or Individual name Tom Hunter, Reg. No. 38,498, Quine Intellectual Property Law Group P.C.						
	Signature	Cly	As				
	Date	June 17, 2002					
			CERTIFICA	ATE OF MAILING	}		
	I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:						
	Typed or printed n	ame Chianti Ap	ppling			0/117/00	
	Signature	1($\overline{}$	Date	06/17/02	

CERTIFICATE OF MAILING										
I hereby certify that this correspondence is being deposited with the Unit envelope addressed to: Assistant Commissioner for Patents, Washingto	ted States Postal Ser in, D.C. 20231 on this	vice as first class mail in an s date: June 17, 2002								
Typed or printed name Chranti Appling										
Signature ()	Date	06/17/02								



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

Quiqe Intellectual Property Law Group, P.C.

Atty Docket No:

300-9038201

Client Ref:

JUN 2 7 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ENTER 1600/2900

In re application of:

AKIRA KOMORIYA and BEVERLY **PACKARD**

Application No.: 09/394,019

Filed: 09/10/1999

COMPOSITIONS FOR THE DETCTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS

OF USE THEREOF

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This document is filed in response to the Communication (paper 24) mailed on May 15, 2002. IN that communication, the Examiner alleged that the replay filed on April 30, 2002 is not fully responsive to the prior Office Action mailed November 21, 2001 (Paper No: 21) because Applicants did not elect one amino acid sequence, one fluorophore, and one hydrophobic group for the elected invention, Group I, claims 1-15.

Applicants note that the Examiner's election of species fails to comply with the requirements of such an election as set forth in MPEP §809.02(a) which states:

Action as follows should be taken:

- Identify generic claims or indicate that no generic claims are present. (A) See MPEP § 806.04(d) for definition of a generic claim.
- (B) Clearly identify each (or in aggravated cases at least exemplary ones) of the disclosed species, to which claims are restricted. The species are preferably identified as the species of figures 1, 2, and 3 or the species of examples I, II, and III, respectively. In the absence of

Examiner: Chih Min Kam

Art Unit: 1653

RESPONSE TO COMMUNICATION

App. No: 09/394,019

Page 2

distinct figures or examples to identify the several species, the mechanical means, the particular material, or other distinguishing characteristic of the species should be stated for each species identified. If the species cannot be conveniently identified, the claims may be grouped in accordance with the species to which they are restricted. [emphasis added]

In the instant case, the Examiner has failed to indicate which claim(s) are generic or to indicate that no generic claims are present. In addition, the Examiner has failed to specifically identify each of the species. Moreover, the particular material, or other distinguishing characteristic of the species has not been stated for each species identified. Indeed, from the Office Action, Applicants cannot ascertain what constitutes a species in the Examiner's opinion, or even how many species are present.


For example, it is unclear whether the Examiner requires an election of a sequence from claim 1, pertaining to particular "P" domains or an election of a sequence from claim 4.

Nevertheless in the interest of compact prosecution, in response to this restriction requirement, Applicants elect s a species within Group I comprising:

- 1) The amino acid sequence: KDPJGLEHDGINGJPKGY (SEQ ID NO:248);
- 2) The fluorophore 9-(2,5 (or 2,6)-dicarboxyphenyl)-3,6-bisamino-xanthylium halide or other anion (Rh110) (item 5 in the Markush Group of claim 9); and
- 3) The hydrophobic group: 9-fluoreneacetyl group (item 2 in the Markush Group of claim 12).

With respect to the listing of claims readable on the elected species, Applicants note that claim 1 is generic and claim 1 and dependent claims 2-12 and 15 are readable on the elected species.

Applicants understand that upon the allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. §1.141.



App. No: 09/394,019

Page 3

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (510) 337-7871.

QUINE INTELLECTUAL PROPERTY LAW

GROUP, P.C.

P.O. BOX 458

Alameda, CA 94501

Tel: 510 337-7871 Fax: 510 337-7877

c:\toms work_amendments\0300 oncoimmunin\300-903820us\300-903820us.am3.doc

Respectfully submitted,

Tom Hunter Reg. No: 38,498